Dr. Daniel Von Hoff, MD, F.A.C.P. Joins Athenex's Clinical Scientific Advisory Board

BUFFALO, N.Y. and HONG KONG, Sept. 15, 2016 /PRNewswire/ -- Athenex Inc., an innovative oncology pharmaceutical company with a broad range of proprietary oncology pharmaceutical products and product candidates under development, is pleased to welcome Dr. Daniel Von Hoff, MD, F.A.C.P. to its Clinical Scientific Advisory Board (SAB).

Dr. Von Hoff is highly regarded as a medical oncologist and drug developer by his colleagues worldwide.  As Physician-in-Chief and Distinguished Professor at the Translational Genomics Research Institute (TGen), Professor of Medicine at the Mayo Clinic, Chief Scientific Officer of the HonorHealth Research Institute, and Medical Director of Research as well as Chief Scientific Officer at US Oncology, Dr. Von Hoff and his team are focused on the development of new anticancer agents and the development of new treatments for patients.  Dr. Von Hoff has been the founder and/or editor of numerous scientific publications including Molecular Cancer Therapeutics and Clinical Cancer Research.  He was also a founder of ILEX ^TM Oncology, a company that had two anti-cancer agents approved by the FDA, Campath and Clolar. The company was sold to Genzyme.  In addition, he has been on both the AACR and American Society of Clinical Oncology Board of Directors, is a past president of the American Association for Cancer Research, is a fellow of the American College of Physicians and was a member of President Bush's National Cancer Advisory Board from 2004 to 2010.

Dr. Rudolf Kwan, Chief Medical Officer of Athenex said, "Dan's remarkable breadth of experience will be a great resource for Athenex. His contributions to the clinical investigation successes of paclitaxel, docetaxel, irinotecan, and nab-paclitaxel will prove invaluable to a number of our existing and planned clinical efforts of our oral portfolio including: Oraxol, Oradoxel and Oratecan.  Further, his current work with new anticancer agents will help Athenex explore additional potential opportunities for KX01 and to further optimize our KX02 program. Dr. Von Hoff has been the recipient of many prestigious awards, has published and lectured extensively, and has provided guidance and inspiration to many clinicians and scientists seeking to develop better cancer treatments for patients." 

About Athenex, Inc.

Founded in 2003, Athenex is a global innovative pharmaceutical company focused on the development and commercialization of next generation therapies for cancer diseases and supportive therapies with a particular emphasis on the China and U.S. markets.  The company is dedicated to delivering innovative drugs that can have a life-changing impact on cancer patients.  The Athenex business includes: three portfolios of innovative proprietary products under development, medical technology research innovation centers, product development and regulatory teams, and existing manufacturing facilities in China and the U.S.  Athenex employees include several hundred professionals dedicated to the mission of improving the lives of cancer patients throughout the world.  With a connected innovation, development and manufacturing presence concentrated in China and the U.S., Athenex can identify, develop, and deliver unique medical technology across continents and multiple regulatory environments.  Athenex has offices in Buffalo and Clarence New York, Cranford New Jersey, Hong Kong, Taipei Taiwan, and multiple locations in Chongqing, China.  In addition to their offices, Athenex has regional development partners in Dunedin New Zealand, Hong Kong, Guangzhou China, Seoul South Korea, Taipei Taiwan, Guatemala City, Guatemala, and Buenos Aires Argentina.

For more information about Athenex's portfolio of proprietary products and clinical studies, please visit www.athenex.com

SOURCE Athenex

Related Links

http://www.athenex.com